Related references
Note: Only part of the references are listed.Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study
Dolors Cuevas et al.
HISTOPATHOLOGY (2020)
Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
A. M. Sofie Berghuis et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer et al.
LANCET ONCOLOGY (2019)
Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma: More Is Better
Aaron R. Huber et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant
Stephanie Robertson et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity: An Institutional Review
Kristen E. Muller et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens
Elizabeth Lokich et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
HER2: An emerging target in colorectal cancer
Megan Greally et al.
CURRENT PROBLEMS IN CANCER (2018)
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
Mari Kylleso Halle et al.
BRITISH JOURNAL OF CANCER (2018)
HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Salvatore Galdy et al.
CANCER AND METASTASIS REVIEWS (2017)
Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers A National Cancer Database Analysis
Mary McGunigal et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Effect of fixation time on breast biomarker expression: a controlled study using cell line-derived xenografted (CDX) tumours
K. R. Kao et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer
Aravind Barathi Asogan et al.
SINGAPORE MEDICAL JOURNAL (2017)
Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer
Miao-Zhen Qiu et al.
JOURNAL OF CANCER (2017)
Optimizing the Quality of Breast Cancer Biomarker Use at Duke Cancer Institute
Arif H. Kamal et al.
Journal of the National Comprehensive Cancer Network (2017)
Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
Alessandro D. Santin et al.
GYNECOLOGIC ONCOLOGY REPORTS (2017)
Practical issues in the diagnosis of serous carcinoma of the endometrium
Sonia Gatius et al.
MODERN PATHOLOGY (2016)
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Angela N. Bartley et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma
Ulas Solmaz et al.
TUMORI (2016)
Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma
Ulas Solmaz et al.
TUMORI (2016)
HER2 Immunohistochemistry Significantly Overestimates HER2 Amplification in Uterine Papillary Serous Carcinomas
Mark J. Mentrikoski et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
HER2/neu in Endometrial Cancer A Promising Therapeutic Target With Diagnostic Challenges
Natalia Buza et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
C. L. Schwab et al.
BRITISH JOURNAL OF CANCER (2014)
Impact of management on the prognosis of pure uterine papillary serous cancer - A Taiwanese Gynecologic Oncology Group (TGOG) study
Chia-Yen Huang et al.
GYNECOLOGIC ONCOLOGY (2014)
Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status
Tao Wang et al.
HUMAN PATHOLOGY (2014)
Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma
Hiroshi Yoshida et al.
VIRCHOWS ARCHIV (2014)
Reliability of core needle biopsy for determining ER and HER2 status in breast cancer
T. J. A. Dekker et al.
ANNALS OF ONCOLOGY (2013)
Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer
Xiaosong Chen et al.
BMC CANCER (2013)
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
Hee Eun Lee et al.
EUROPEAN JOURNAL OF CANCER (2013)
Marked Heterogeneity of HER2/NEU Gene Amplification in Endometrial Serous Carcinoma
Natalia Buza et al.
GENES CHROMOSOMES & CANCER (2013)
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Natalia Buza et al.
MODERN PATHOLOGY (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis
Xiaosong Chen et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer: A Prospective Study
Leung Chu Tong et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
K. El-Sahwi et al.
BRITISH JOURNAL OF CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
M. Arnedos et al.
ANNALS OF ONCOLOGY (2009)
A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study
Howard D. Homesley et al.
GYNECOLOGIC ONCOLOGY (2009)
Delay to formalin fixation effect on breast biomarkers
Thaer Khoury et al.
MODERN PATHOLOGY (2009)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Alessandro D. Santin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2008)
HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
J. A. Villella et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HEr2 status of the whole tumor
E Mueller-Holzner et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Share Paper
